Browse medicines
Some records contain detailed evidence; others currently contain only basic identity and regulatory information. Reviewed conclusions appear only when they are available for a specific use and group of people.
Showing 1–60 of 526 records
Abatacept (Orencia)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Moderately to severely active rheumatoid arthritis
Anakinra (Kineret)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Neonatal-Onset Multisystem Inflammatory Disease
Beta-Glucosidase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordFollitropin (Follistim Aq / Gonal-F Rff Redi-Ject)
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordUse listed on the medicine record
FOLLISTIM ® AQ Cartridge (follitropin beta) injection, is indicated: In Women for: FOLLISTIM AQ Cartridge is a gonadotropin indicated: In Women for: Induction of Ovulation and Pregnancy in Anovulatory Infertile Women in Whom the Cause of Infertility is Functional and Not Due to Primary Ovarian Failure ( 1.1 ) Pregnancy in Normal Ovulatory Women Undergoing Controlled Ovarian Stimulation as Part of an In Vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI) Cycle ( 1.2 ) In Men for: Induction of Spermatogenesis in Men with Primary and Secondary Hypogonadotropic Hypogonadism (HH)…
Aflibercept-Abzv (Enzeevu)
Protein medicineApproved in the United States (FDA)Expanded recordBelatacept (Nulojix)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Prophylaxis of organ rejection
Beta Glucanase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordCatkin
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordInsulin Human (Humulin R / Novolin 70/30 / Afrezza / Myxredlin / Novolin N / Humulin R U-500)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Glycemic control
4-Phytase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordAdalimumab-Ryvk (Simlandi)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
SIMLANDI is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA): Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. ( 1.1 ) Juvenile Idiopathic Arthritis (JIA): Reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older.
Catalase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordCertolizumab pegol (Cimzia)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Moderately to severely active rheumatoid arthritis
Conestat alfa (Ruconest)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Acute attacks
Human Peripheral Nerve Tissue (Avance Nerve Graft)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Adult and pediatric patients aged one month and older
Human Vaccinia Virus Immune Globulin (Cnj-016)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Complications due to vaccinia vaccination ( 1 ), including
Insulin Aspart-Szjj (Merilog)
Protein medicineApproved in the United States (FDA)Expanded recordInsulin Lispro-Aabc (Lyumjev)
Protein medicineApproved in the United States (FDA)Expanded recordPegfilgrastim-Pbbk (Fylnetra)
Protein medicineApproved in the United States (FDA)Expanded recordAcellular Tissue Engineered Vessel (Symvess)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
As a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein
Adalimumab-Adaz (Hyrimoz)
Protein medicineApproved in the United States (FDA)Expanded recordAdalimumab-Adbm (Cyltezo)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Adalimumab-adbm is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
Adalimumab-Atto (Amjevita)
Protein medicineApproved in the United States (FDA)Expanded recordAflibercept-Mrbb (Ahzantive)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
These highlights do not include all the information needed to use AHZANTIVE safely and effectively. See full prescribing information for AHZANTIVE. Initial U.S. Approval: 2024 1 INDICATIONS AND USAGE AHZANTIVE is indicated for the treatment of: 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) AHZANTIVE is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD)…
Agalsidase beta (Fabrazyme)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Adult and pediatric patients 2 years of age and older with confirmed Fabry disease
Albumin Aggregated (Pulmotech Maa / Draximage Maa)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
DRAXIMAGE MAA, after radiolabeling with sodium pertechnetate Tc 99m, is indicated for: Lung scintigraphy as an adjunct in the evaluation of pulmonary perfusion in adults and pediatric patients. Peritoneovenous shunt scintigraphy as an aid in the evaluation of its patency in adult patients. DRAXIMAGE MAA, after radiolabeling with sodium pertechnetate Tc 99m, is a radioactive diagnostic agent indicated for: Lung scintigraphy as an adjunct in the evaluation of pulmonary perfusion in adults and pediatric patients.
Denosumab-Kyqq (Aukelso / Bosaya)
Protein medicineApproved in the United States (FDA)Expanded recordGemtuzumab Ozogamicin (Mylotarg)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Newly-diagnosed CD33-positive acute myeloid leukemia
Metreleptin (Myalept)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
The complications of leptin deficiency
Pegvisomant (Somavert)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Acromegaly
Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (Phesgo)
Protein medicineApproved in the United States (FDA)Expanded recordSummer Flounder (Flounder)
Protein medicineLaboratory or animal-stage researchExpanded recordTaliglucerase alfa (Elelyso)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Patients 4 years of age and older with a confirmed diagnosis of Type 1 Gaucher disease
Tividenofusp alfa (Avlayah)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
AVLAYAH is indicated for the treatment of neurologic manifestations of Hunter syndrome (Mucopolysaccharidosis type II, MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment. This indication is approved under accelerated approval based on the reduction of cerebrospinal fluid heparan sulfate [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Adalimumab-Aaty (Yuflyma)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
YUFLYMA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active r heumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
Adalimumab-Afzb (Abrilada)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
ABRILADA is a tumor necrosis factor (TNF) blocker indicated for: • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) • Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
Adalimumab-Aqvh (Yusimry)
Protein medicineApproved in the United States (FDA)Expanded recordAdalimumab-Bwwd (Hadlima)
Protein medicineApproved in the United States (FDA)Expanded recordAdalimumab-Fkjp (Hulio)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Adalimumab-fkjp is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. J uvenile Idiopathic Arthritis (JIA) ( 1.2 ) : reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older.
Allogeneic Thymocyte-Depleted Thymus Tissue-Agdc (Rethymic)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Immune reconstitution
American Lobster (Maine Lobster / Lobster)
Protein medicineLaboratory or animal-stage researchExpanded recordAminopeptidase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordAtlantic Mackerel (Mackerel)
Protein medicineLaboratory or animal-stage researchExpanded recordBerahyaluronidase alfa (Keytruda)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Unresectable or metastatic melanoma
Bordetella Pertussis Filamentous Hemagglutinin Antigen (Boostrix / Pediarix / Daptacel / Quadracel / Kinrix / Vaxelis)
Protein medicineLaboratory or animal-stage researchExpanded recordCalaspargase Pegol-Mknl (Asparlas)
Protein medicineApproved in the United States (FDA)Expanded recordCerliponase alfa (Brineura)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
The loss of ambulation
Collagen, Soluble, Fish Skin (Massage Cream For Stretch Marks / Aoao Retinol Anti-Aging Box Set / A0a0 Rice Ceramide Anti Wrinkle Age Essence Box Set / Aoa0 Snail Ginseng Cream)
Protein medicineApproved in the United States (FDA)Expanded recordCrovalimab-Akkz (Piasky)
Protein medicineApproved in the United States (FDA)Expanded recordDarbepoetin alfa (Aranesp)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Anemia due
Denileukin Diftitox-Cxdl (Lymphir)
Protein medicineApproved in the United States (FDA)Expanded recordDenosumab-Adet (Ponlimsi)
Protein medicineApproved in the United States (FDA)Expanded recordDenosumab-Bnht (Conexxence / Bomyntra)
Protein medicineApproved in the United States (FDA)Expanded recordDenosumab-Dssb (Ospomyv / Xbryk)
Protein medicineApproved in the United States (FDA)Expanded recordDenosumab-Nxxp (Bilprevda / Bildyos)
Protein medicineApproved in the United States (FDA)Expanded recordDiamine Oxidase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordEastern Oyster (Oyster)
Protein medicineLaboratory or animal-stage researchExpanded recordFaricimab-Svoa (Vabysmo)
Protein medicineApproved in the United States (FDA)Expanded recordGlucoamylase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordHaemophilus Influenzae Type B Capsular Polysaccharide Meningococcal Outer Membrane Protein Conjugate Antigen (Pedvaxhib)
Protein medicineLaboratory or animal-stage researchExpanded record